Lead Product(s) : Sabin Strain Based Inactivated Polio Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Sinovac Biotech
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The approval of Sinovac’s polio vaccine (sIPV) by the NMPA in China is a major milestone in the ongoing efforts towards global polio eradication & to reduce the vaccine-associated paralytic polio caused by oral polio vaccines, which are based on live a...
Product Name : sIPV
Product Type : Vaccine
Upfront Cash : Inapplicable
July 20, 2021
Lead Product(s) : Sabin Strain Based Inactivated Polio Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Sinovac Biotech
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sabin Inactivated Polio Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Intravacc’s Sabin-IPV Vaccine Eupolio Receives WHO Prequalification to Treat Poliomyelitis
Details : Eupolio was developed by Intravacc for technology transfer to manufacturers in low- and middle-income countries in the context of the global polio eradication initiative. Eupolio™ received the prequalification status from the WHO by the end of December...
Product Name : Eupolio
Product Type : Vaccine
Upfront Cash : Inapplicable
January 21, 2021
Lead Product(s) : Sabin Inactivated Polio Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Recombinant Human Alkaline Phosphatase
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AM-Pharma Enrolls First Patient in Japan for Ongoing Phase III SA-AKI Pivotal REVIVAL Trial
Details : The REVIVAL trial is a Phase III pivotal study evaluating AM-Pharma’s proprietary recombinant alkaline phosphatase, ilofotase alfa, for the treatment of patients with SA-AKI.
Product Name : Ilofotase Alfa
Product Type : Protein
Upfront Cash : Inapplicable
January 07, 2021
Lead Product(s) : Recombinant Human Alkaline Phosphatase
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ChAdOx1 nCoV-19
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : AstraZeneca
Deal Size : Undisclosed
Deal Type : Collaboration
HALIX Signs Agreement With AstraZeneca For Commercial Manufacture Of COVID-19 Vaccine
Details : Under the agreement, HALIX will provide commercial manufacturing of drug substance at its state-of-the-art cGMP facility at the Leiden Bio Science Park in the Netherlands. To meet the increased demand, HALIX expands with two additional viral vector produ...
Product Name : AZD1222
Product Type : Vaccine
Upfront Cash : Undisclosed
August 12, 2020
Lead Product(s) : ChAdOx1 nCoV-19
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : AstraZeneca
Deal Size : Undisclosed
Deal Type : Collaboration